|
|
Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT
|
|
|
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
|
|
|
Delcath Systems Closes $7 Million Private Placement
|
|
|
Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call
|
|
|
Delcath Systems Appoints Martha S. Rook as Chief Operating Officer
|
|
|
Delcath Systems Announces $7 Million Private Placement
|
|
|
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Delcath Systems to Participate in Upcoming Investor Conferences
|
|
|
Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)
|
|
|
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024
|
|
|
Delcath Systems to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
|
|
|
Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT™
|
|
|
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|